Adaptive ultra-hypofractionated whole-pelvic radiotherapy in high-risk and very high-risk prostate cancer on 1.5-Tesla MR-Linac: Estimated delivered dose and early toxicity results.

Lin-Rui GaoRan WeiShirui QinYuan TianWenlong XiaYongwen SongShulian WangHui FangYu TangHao JingYueping LiuYuan TangShunan QiBo ChenYexiong LiNianzeng XingNingning Lu

Published in: Chronic diseases and translational medicine (2024)

Chinese Clinical Trial Registry ChiCTR2000033382.

Keyphrases

prostate cancer
clinical trial
radiation therapy
magnetic resonance
radical prostatectomy
early stage
rectal cancer
locally advanced
oxidative stress
contrast enhanced
open label
study protocol
phase ii
magnetic resonance imaging
squamous cell carcinoma
randomized controlled trial
small cell lung cancer
phase iii